Know ALL, a new global community in acute lymphoblastic leukemia, has launched!

We are pleased to announce the launch of Know ALL, a global education and awareness initiative that focuses solely on acute lymphoblastic leukemia (ALL), with the aim to provide patients and caregivers with information, resources, and support to deal with ALL. Know ALL is guided by a highly experienced global ambassador group who meet regularly to ensure the voice of patients and their families is at the core of the initiative. 

Founded in 2022, Know ALL is a collaboration between Scientific Education Support (SES) and the Acute Leukemia Advocates Network (ALAN). ALAN is a global network of patient advocates who are collaborating with SES on Know ALL to ensure that the ALL community has access to the latest information and resources, providing the best possible support and care for patients with ALL and their families. 

SES and ALAN would like to acknowledge support, through independent grants, from Amgen and Jazz Pharmaceuticals, without whom the launch of this initiative would not have been possible. 

With the mission to drive awareness of ALL globally, we are seeking further industry support through independent grants for Know ALL to deliver upon a number of key objectives, particularly the sharing and exchanges of medical advances in ALL. Among the priority educational gaps identified by the ambassador group is the need for education on treatment, including emerging therapies, age related protocols, and other considerations linked to treatment. 

By funding Know ALL, we believe that industry can help support the educational needs of the ALL community as well as receive valuable insights into the patient experience. We would be delighted to welcome interested industry parties to support the initiative. 

 “Know ALL is important because all cancers should have individual representation. The Know ALL initiative will provide the space for both current, past, and future patients with ALL to access high-quality information about their cancer, both from each other and from experts. I’m proud of Know ALL because it provides visibility for a not often spoken about cancer, and it is something using the voices of the people ALL affects to build resources that patients with ALL will find useful.” Jaymz Goodman, a patient in remission from ALL and a Know ALL ambassador. 

Please contact the partnerships team for more information on how to support this initiative. 

For more information on Know ALL, please visit know-alleukemia.com or contact ses_knowall@scientificeducationsupport.com. 

Connect with our social channels: 

Twitter: @_KNOW_ALL 

Facebook: Know ALL 

LinkedIn: Know ALL 

Instagram: know.all2021